<b>Cytokines in leprosy, II. Effect of treatment on serum cytokines in leprosy</b>

Moubasher, Alaa; Kamel, Neveen A.; Zedan, Hatem; Raheem, Diaa El‐Din Abdel

doi:10.1046/j.1365-4362.1998.00382.x

Cited by 21 publications

(14 citation statements)

References 17 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This finding disagrees with that of Moubascher et al 16 , who demonstrated a significant reduction in IL-1β serum levels and other molecules (IL-2R and IL-10) after one year of treatment in 36 leprosy cases. However, for this analysis, the present sample consisted of only seven patients, being considered too small for the researchers to make inferences.…”

Section: Discussioncontrasting

confidence: 99%

“…This finding agrees with that observed by Moubasher et al 16 , in which nontreated leprosy patients exhibited significantly higher IL-1β serum levels and other molecules (IFN -γ, IL-2R, IL-10 and TNF-α) detected by the ELISA test compared to healthy controls. Therefore, we may deduce that IL-1β release in leprosy cases is an indication of the activation of a cell-mediated immune response to the bacillus, according to the observation of Watson et al 35 , who quantified the production of IL-1β and IL-2 by mononuclear adhering cells from the peripheral blood of patients with different forms of leprosy.…”

Section: Discussionsupporting

confidence: 93%

See 1 more Smart Citation

Avaliação da expressão de interleucina 1 beta (IL-1β) e antagonista do receptor de interleucina 1 (IL-1Ra) em pacientes com hanseníase

Costa

Mendonça

Lyon

et al. 2008

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Leprosy is an infectious and contagious spectral disease accompanied by a series of immunological events triggered by the host's response to the etiologic agent, Mycobacterium leprae. Evidence suggests that the induction and maintenance of the immune/inflammatory response in leprosy are linked to multiple cell interactions and soluble factors, mainly through the action of cytokines. The ELISA test was used to measure the levels of IL-1β and IL-1Ra in 37 new leprosy patients followed-up during treatment and 30 healthy controls. Peripheral blood was collected four times during the treatment of leprosy patients (MDT pretreatment, 2 nd dose, 6 th dose and post-MDT), and only once from the controls. The comparison of molecular levels in pre-MDT patients and controls showed a statistically significant difference for IL-1β. The results suggest the participation of this cytokine in the genesis of the immune/inflammatory process. Key-words:Leprosy. Interleukins. IL-1β and IL-1Ra. RESUMOA hanseníase é uma doença infectocontagiosa espectral que acompanha-se por uma série de eventos imunológicos desencadeados pela resposta do hospedeiro frente ao agente etiológico, o Mycobacterium leprae. Evidências sugerem que a indução e manutenção da resposta imune/inflamatória na hanseníase estão vinculadas a interações de múltiplas células e fatores solúveis, particularmente através da ação de citocinas. Nesse estudo, foram mensurados níveis de IL-1β e IL-1Ra de 37 casos novos de hanseníase acompanhados ao longo do tratamento e 30 controles sadios pelo teste ELISA. A coleta de sangue periférico foi realizada em quatro tempos para os casos de hanseníase (pré-tratamento com PQT, 2ª dose, 6ª dose e pós-PQT) e em único momento para os controles. Na comparação dos níveis das moléculas de casos no pré-PQT e controles, houve diferença estatisticamente significativa somente para IL-1β. Nossos resultados sugerem a participação dessa citocina no processo imune/inflamatório. Palavras-chaves:Hanseníase. Interleucinas. IL-1β e IL-1Ra. Leprosy is a chronic infectious and parasitic disease caused by Mycobacterium leprae, an atoxic, resistant, acid-alcohol-fast, obligate intracellular bacillus, which induces an extraordinary cell-mediated immune response in diseased individuals and affects mainly the skin and branches of peripheral nerves 4 17 19 20 .Neural injury, recognized by many authors as the most serious complication of leprosy, is triggered by infection and accompanied by a series of immunological events, whose evolution sequelae often last many years after infection has ceased 22 28 . It presents an important peculiarity to clinicians and immunologists: the host's diversity in responding to its etiologic agent imposes a diagnostic challenge and an excellent model for understanding cellular immunity in humans 23 .Leprosy is characterized by its high infectivity and low pathogenicity; moreover, more than 95% of the population are naturally immune to such an infection 18 31 32 33 . This condition can be changed in function of the relatio...

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussionsupporting

confidence: 93%

Avaliação da expressão de interleucina 1 beta (IL-1β) e antagonista do receptor de interleucina 1 (IL-1Ra) em pacientes com hanseníase

Costa

Mendonça

Lyon

et al. 2008

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

show abstract

“…In this case, cytokine of leprosy patients produced as response to immune stimulation by M. leprae antigen, and when this antigen reduced after treatment, cytokine production also decreased and it may reduced to normal level as in healthy subject if this antigen is totally diminished [15].…”

Section: Discussionmentioning

confidence: 83%

Interleukin-12 and Interleukin-4 Levels of Multibacillary Leprosy Patients Before and After Rifampicine Ofloxacine Minocycline Combined Therapy

Budhiani¹

2017

AJCEM

View full text Add to dashboard Cite

Abstract:Leprosy is a chronic infectious disease caused by Mycobacterium leprae, which is an obligate intracellular bacteria. This study aims to determine the interleukin-12 and interleukin-4 levels of multibacillary leprosy patients before and after Rifampicine Ofloxacine Minocycline (ROM) combined therapy for three months. The research used an analytic observational design with the prospective cohort study pre and post treatment method. The samples were taken at the polyclinic of Skin Treatment Central Public hospital and Ibnu Sina hospital. Samples examination was conducted in the NECHRI laboratory, Hasanuddin University Teaching hospital. The samples were ten new patients of MB type leprosy. Blood samples were taken before and after the ROM therapy for three months. The levels of interleukin-12 and interleukin-4 were assessed using the ELISA technique. The results shows that there is no significant change in the levels of interleukin-12 and interleukin-4 in the patients of multibacillary leprosy before and after ROM therapy for three months.

show abstract

“…Regarding the TLR4 gene, we observed greater production of IL-1-β and IL-17 between carriers of the A allele in the exonic SNP rs1927914. IL1-β is essential for the amplification of the T-cells specific immune response and its levels tend to decrease after the multidrug therapy (Moubasher et al 1998). This cytokine is also produced in high concentrations in multibacillary patients (Madan et al 2011).…”

Section: Discussionmentioning

confidence: 99%

Polymorphisms in genes TLR1, 2 and 4 are associated with differential cytokine and chemokine serum production in patients with leprosy

Santana

Rêgo

Oliveira

et al. 2017

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

BACKGROUND Leprosy or hansen’s disease is a spectral disease whose clinical forms mostly depends on host’s immune and genetic factors. Different Toll-like receptors (TLR) variants have been described associated with leprosy, but with some lack of replication across different populations.OBJECTIVES To evaluate the role of polymorphisms in genes TLR1, TLR2 and TLR4 and susceptibility to leprosy in a genetic case control study; to verify the association between genotypes of these markers and the immunological profile in the serum of patients with leprosy.METHODS Pre-designed TaqMan® assays were used to genotype markers at TLR1 (rs4833095, rs5743551), TLR2 (rs7656411, rs3804099) and TLR4 (rs1927914, rs1927911). A panel of cytokines and chemokines was accessed by enzime-linked immunosorbent assay (ELISA) test in the serum of a subgroup of patients with and without leprosy reactions.FINDINGS Our results show an association between the T allele of rs3804099 at the TLR2 gene and increased risk for leprosy per se [Odds ratio (OR) = 1.296, p = 0,022]. In addition, evaluating the association between different genotypes of the TLR1, 2 and 4 markers and cytokine/chemokine serological levels, IL-17 appears as an immunological marker regulated by the polymorphism of the three TLR genes evaluated, whereas different TLR1 genotypes were associated with differential production of IL-12p40 and MCP-1(CCL2). Furthermore, other relevant serum markers such as CXCL-10 and IL-6 seemed to be regulated by TLR2 variants and IL-1β was related to TLR4 genotypes.MAIN CONCLUSIONS All together our data points that the tested TLR markers may have a regulatory role in the immunity against Mycobacterium leprae, by driving the host’s production of key cytokines and chemokines involved in the pathogenesis of this disease.

show abstract

Cytokines in leprosy, II. Effect of treatment on serum cytokines in leprosy

Abstract: MDT caused a reduction in serum cytokines correlated with a reduction in the bacterial burden. It is advisable to continue MDT for PB patients for 1 year. Serum IL-1beta levels may have a prognostic value for the susceptibility of leprosy patients to the development of reactions.

Cited by 21 publications

References 17 publications

Avaliação da expressão de interleucina 1 beta (IL-1β) e antagonista do receptor de interleucina 1 (IL-1Ra) em pacientes com hanseníase

Avaliação da expressão de interleucina 1 beta (IL-1β) e antagonista do receptor de interleucina 1 (IL-1Ra) em pacientes com hanseníase

Interleukin-12 and Interleukin-4 Levels of Multibacillary Leprosy Patients Before and After Rifampicine Ofloxacine Minocycline Combined Therapy

Polymorphisms in genes TLR1, 2 and 4 are associated with differential cytokine and chemokine serum production in patients with leprosy

Contact Info

Product

Resources

About